Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers

Tuberculosis (TB) continues to be a serious threat to public health throughout the world. Newer treatments are needed that could offer simplified regimens with activity against both drug‐sensitive and drug‐resistant bacilli, while optimizing safety. Pretomanid (PA‐824), a nitroimidazooxazine compoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengchun, Saviolakis, George A., El‐Amin, Wael, Makhene, Mamodikoe K., Osborn, Blaire, Nedelman, Jerry, Yang, Tian J., Everitt, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246780/
https://www.ncbi.nlm.nih.gov/pubmed/33378139
http://dx.doi.org/10.1002/cpdd.898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246780/
https://www.ncbi.nlm.nih.gov/pubmed/33378139
http://dx.doi.org/10.1002/cpdd.898

Ejemplares similares